marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
Mersana Therapeutics Balance Sheet 2011-2024 | MRSN
Annual Balance Sheet Mersana Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-148 M | -101 M | -151 M | -249 M | -57.5 M | -59.6 M | -26.6 M | -100 M | -11.5 M | - | - | - | - |
Long Term Debt |
23.1 M | 24.9 M | 24.6 M | 4.98 M | 4.2 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.25 M | 2.8 M | 2.3 M | 1.44 M | 2.22 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 5.15 M | 282 K | 28.8 M | 132 M | 46.4 M | - | - | - | - |
Total Current Liabilities |
63.6 M | 91.5 M | 47.5 M | 30 M | 24.1 M | 69.4 M | 31.9 M | - | - | - | - | - | - |
Total Liabilities |
189 M | 242 M | 84.4 M | 45.3 M | 29.2 M | 69.7 M | 60.7 M | 161 M | 57.1 M | - | - | - | - |
Deferred Revenue |
28.1 M | 30.6 M | 3.94 M | 3.99 M | 4.82 M | 46.2 M | 21.6 M | 22.7 M | 7.05 M | - | - | - | - |
Retained Earnings |
-826 M | -655 M | -450 M | -280 M | -192 M | -164 M | -97.9 M | -59.2 M | -45.5 M | - | - | - | - |
Total Assets |
226 M | 334 M | 206 M | 273 M | 108 M | 78.5 M | 131 M | 105 M | 14.4 M | - | - | - | - |
Cash and Cash Equivalents |
175 M | 129 M | 178 M | 255 M | 62.4 M | 59.6 M | 26.6 M | 100 M | - | - | - | - | - |
Book Value |
36.9 M | 92.1 M | 122 M | 228 M | 78.3 M | 8.8 M | 70 M | -55.6 M | -42.7 M | - | - | - | - |
Total Shareholders Equity |
36.9 M | 92.1 M | 122 M | 228 M | 78.3 M | 8.8 M | 70 M | -55.6 M | -42.7 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Mersana Therapeutics
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
14 M | 17 M | 23.1 M | 25 M | 25 M | 25 M | 24.9 M | 25 M | 25 M | 25 M | 24.6 M | 5.2 M | 5.03 M | 5.2 M | 4.98 M | 4.94 M | 3.26 M | 3.73 M | 4.2 M | 4.2 M | 4.2 M | 4.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
168 M | 171 M | 189 M | 211 M | 221 M | 232 M | 242 M | 225 M | 118 M | 118 M | 84.4 M | 62 M | 58.2 M | 50 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 29.2 M | 29.2 M | 29.2 M | 29.2 M | 69.7 M | 69.7 M | 69.7 M | 69.7 M | 60.7 M | 60.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
31.4 M | 29.3 M | 28.1 M | 21.6 M | 20.5 M | 28.8 M | 30.6 M | 30.9 M | 26.2 M | 16.6 M | 3.94 M | 3.96 M | 3.97 M | 3.98 M | 3.99 M | 3.99 M | 3.99 M | 3.99 M | 4.82 M | 4.82 M | 4.82 M | 4.82 M | 46.2 M | 46.2 M | 46.2 M | 46.2 M | 21.6 M | 16.5 M | 24.9 M | 21.6 M | 22.7 M | 22.7 M | 22.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-881 M | -870 M | -826 M | -807 M | -765 M | -711 M | -655 M | -610 M | -550 M | -498 M | -450 M | -401 M | -356 M | -315 M | -280 M | -280 M | -280 M | -280 M | -192 M | -192 M | -192 M | -192 M | -164 M | -164 M | -164 M | -164 M | -97.9 M | -97.9 M | -97.9 M | -97.9 M | -59.2 M | -59.2 M | -59.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
170 M | 179 M | 226 M | 263 M | 311 M | 296 M | 334 M | 315 M | 252 M | 258 M | 206 M | 218 M | 254 M | 248 M | 273 M | 273 M | 273 M | 273 M | 108 M | 108 M | 108 M | 108 M | 78.5 M | 78.5 M | 78.5 M | 78.5 M | 131 M | 131 M | 131 M | 131 M | 105 M | 105 M | 105 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
78.9 M | 59 M | 175 M | 186 M | 129 M | 123 M | 129 M | 184 M | 135 M | 230 M | 178 M | 192 M | 227 M | 228 M | 255 M | 255 M | 255 M | 255 M | 62.4 M | 62.4 M | 62.4 M | 62.4 M | 59.6 M | 59.6 M | 59.6 M | 59.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 100 M | 100 M | 100 M | - | 11.5 M | - | - | - | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.05 M | 8.43 M | 36.9 M | 52.2 M | 89.8 M | 64.3 M | 92.1 M | 90.2 M | 134 M | 141 M | 122 M | 156 M | 196 M | 198 M | 228 M | 228 M | 228 M | 228 M | 78.3 M | 78.3 M | 78.3 M | 78.3 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 70 M | 70 M | 131 M | 131 M | 105 M | 105 M | 105 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.05 M | 8.43 M | 36.9 M | 52.2 M | 89.8 M | 64.3 M | 92.1 M | 90.2 M | 134 M | 141 M | 122 M | 156 M | 196 M | 198 M | 228 M | 228 M | 228 M | 228 M | 78.3 M | 78.3 M | 78.3 M | 78.3 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 70 M | 70 M | 70 M | 70 M | -55.6 M | -55.6 M | -55.6 M | - | -42.7 M | - | - | - | -26.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency